Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease

Torsten Falk, Xu Yue, Shiling Zhang, Alexander D. McCourt, Brandon J. Yee, Robert T. Gonzalez, Scott J Sherman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Developing novel neuroprotective strategies for the treatment of Parkinson's disease (PD) is of great importance. We have previously shown that vascular endothelial growth factor-B (VEGF-B) is up-regulated in an in vitro model of PD using the neurotoxin rotenone. Addition of exogenous VEGF-B167 was neuroprotective in this same model, suggesting that VEGF-B is a natural response to neurodegenerative challenges. Now we have extended this research using in vivo experiments. We tested a single intra-striatal injection of 3μg VEGF-B186, the more diffusible VEGF-B isoform, in a mild progressive unilateral 6-hydroxydopamine (6-OHDA) rat in vivo PD model. Treatment with VEGF-B186 6h prior to lesioning with 6-OHDA improved amphetamine-induced rotations and forepaw preference at 2, 4 and 6 weeks post-injection, indicating a neuroprotective effect. Immunohistochemical analysis showed that VEGF-B186 treatment partially protected dopaminergic fibers in the striatum and demonstrated a partial rescue of the dopaminergic neurons in the caudal sub-region of the substantia nigra. Altogether our data suggest that VEGF-B186 could be a new candidate trophic factor for the treatment of PD.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalNeuroscience Letters
Volume496
Issue number1
DOIs
StatePublished - May 27 2011

Fingerprint

Vascular Endothelial Growth Factor B
Vascular Endothelial Growth Factor A
Parkinson Disease
Oxidopamine
Corpus Striatum
Rotenone
Injections
Dopaminergic Neurons
Neurotoxins
Neuroprotective Agents
Substantia Nigra
Amphetamine
Therapeutics
Protein Isoforms
Research

Keywords

  • 6-OHDA lesion
  • Midbrain culture
  • Neurotrophic therapy
  • VEGF-B167
  • VEGF-B186

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. / Falk, Torsten; Yue, Xu; Zhang, Shiling; McCourt, Alexander D.; Yee, Brandon J.; Gonzalez, Robert T.; Sherman, Scott J.

In: Neuroscience Letters, Vol. 496, No. 1, 27.05.2011, p. 43-47.

Research output: Contribution to journalArticle

Falk, Torsten ; Yue, Xu ; Zhang, Shiling ; McCourt, Alexander D. ; Yee, Brandon J. ; Gonzalez, Robert T. ; Sherman, Scott J. / Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease. In: Neuroscience Letters. 2011 ; Vol. 496, No. 1. pp. 43-47.
@article{ce2c674195534e129e1339fa5a222e89,
title = "Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease",
abstract = "Developing novel neuroprotective strategies for the treatment of Parkinson's disease (PD) is of great importance. We have previously shown that vascular endothelial growth factor-B (VEGF-B) is up-regulated in an in vitro model of PD using the neurotoxin rotenone. Addition of exogenous VEGF-B167 was neuroprotective in this same model, suggesting that VEGF-B is a natural response to neurodegenerative challenges. Now we have extended this research using in vivo experiments. We tested a single intra-striatal injection of 3μg VEGF-B186, the more diffusible VEGF-B isoform, in a mild progressive unilateral 6-hydroxydopamine (6-OHDA) rat in vivo PD model. Treatment with VEGF-B186 6h prior to lesioning with 6-OHDA improved amphetamine-induced rotations and forepaw preference at 2, 4 and 6 weeks post-injection, indicating a neuroprotective effect. Immunohistochemical analysis showed that VEGF-B186 treatment partially protected dopaminergic fibers in the striatum and demonstrated a partial rescue of the dopaminergic neurons in the caudal sub-region of the substantia nigra. Altogether our data suggest that VEGF-B186 could be a new candidate trophic factor for the treatment of PD.",
keywords = "6-OHDA lesion, Midbrain culture, Neurotrophic therapy, VEGF-B167, VEGF-B186",
author = "Torsten Falk and Xu Yue and Shiling Zhang and McCourt, {Alexander D.} and Yee, {Brandon J.} and Gonzalez, {Robert T.} and Sherman, {Scott J}",
year = "2011",
month = "5",
day = "27",
doi = "10.1016/j.neulet.2011.03.088",
language = "English (US)",
volume = "496",
pages = "43--47",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease

AU - Falk, Torsten

AU - Yue, Xu

AU - Zhang, Shiling

AU - McCourt, Alexander D.

AU - Yee, Brandon J.

AU - Gonzalez, Robert T.

AU - Sherman, Scott J

PY - 2011/5/27

Y1 - 2011/5/27

N2 - Developing novel neuroprotective strategies for the treatment of Parkinson's disease (PD) is of great importance. We have previously shown that vascular endothelial growth factor-B (VEGF-B) is up-regulated in an in vitro model of PD using the neurotoxin rotenone. Addition of exogenous VEGF-B167 was neuroprotective in this same model, suggesting that VEGF-B is a natural response to neurodegenerative challenges. Now we have extended this research using in vivo experiments. We tested a single intra-striatal injection of 3μg VEGF-B186, the more diffusible VEGF-B isoform, in a mild progressive unilateral 6-hydroxydopamine (6-OHDA) rat in vivo PD model. Treatment with VEGF-B186 6h prior to lesioning with 6-OHDA improved amphetamine-induced rotations and forepaw preference at 2, 4 and 6 weeks post-injection, indicating a neuroprotective effect. Immunohistochemical analysis showed that VEGF-B186 treatment partially protected dopaminergic fibers in the striatum and demonstrated a partial rescue of the dopaminergic neurons in the caudal sub-region of the substantia nigra. Altogether our data suggest that VEGF-B186 could be a new candidate trophic factor for the treatment of PD.

AB - Developing novel neuroprotective strategies for the treatment of Parkinson's disease (PD) is of great importance. We have previously shown that vascular endothelial growth factor-B (VEGF-B) is up-regulated in an in vitro model of PD using the neurotoxin rotenone. Addition of exogenous VEGF-B167 was neuroprotective in this same model, suggesting that VEGF-B is a natural response to neurodegenerative challenges. Now we have extended this research using in vivo experiments. We tested a single intra-striatal injection of 3μg VEGF-B186, the more diffusible VEGF-B isoform, in a mild progressive unilateral 6-hydroxydopamine (6-OHDA) rat in vivo PD model. Treatment with VEGF-B186 6h prior to lesioning with 6-OHDA improved amphetamine-induced rotations and forepaw preference at 2, 4 and 6 weeks post-injection, indicating a neuroprotective effect. Immunohistochemical analysis showed that VEGF-B186 treatment partially protected dopaminergic fibers in the striatum and demonstrated a partial rescue of the dopaminergic neurons in the caudal sub-region of the substantia nigra. Altogether our data suggest that VEGF-B186 could be a new candidate trophic factor for the treatment of PD.

KW - 6-OHDA lesion

KW - Midbrain culture

KW - Neurotrophic therapy

KW - VEGF-B167

KW - VEGF-B186

UR - http://www.scopus.com/inward/record.url?scp=79955595805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955595805&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2011.03.088

DO - 10.1016/j.neulet.2011.03.088

M3 - Article

VL - 496

SP - 43

EP - 47

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -